RxDoctor Payments Data

Susan Healy

Nurse Practitioner · Salinas, CANPI 1023267028

Payments from drug & device makers

$287in general payments, 2019–2025

Across 14 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$41
  • Medtronic$33
  • Novartis$29
  • Abbott$25
  • Mannkind Corporation$24
  • Embecta Corp.$23
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$287 in reported general payments places this provider in the 60th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$11,224
Medicare patients
78
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin287$239,329
OzempicSemaglutide172$186,102
TrulicityDulaglutide113$131,905
Fiasp FlextouchInsulin Aspart (Niacinamide)40$34,785
MounjaroTirzepatide29$30,257
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog67$25,429
Victoza 3-PakLiraglutide17$24,347
Tresiba Flextouch U-100Insulin Degludec44$24,175
TradjentaLinagliptin24$20,347
JanuviaSitagliptin Phosphate18$18,412
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$16,872
Tresiba Flextouch U-200Insulin Degludec19$13,946
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$12,939
Novolog FlexpenInsulin Aspart35$10,750
JanumetSitagliptin Phos/Metformin Hcl12$9,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$18$259,676311 claims
Novo NordiskOzempic$41$186,102172 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$17$165,489155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →